ndi

Non-innovator biologicals in India: regulatory context and areas for improvement

There are major regulatory lapses in the manufacturing of similar biologics in India. The use of scientific audits could strengthen the regulatory system and improve the provision of high quality biosimilars in the country, according to a recent opinion piece [1] by Dr GR Soni, which was published in GaBI Journal.




ndi

The Frieden Health Defense Funding Proposition

Congress is starting to consider ways to address the budget cap problem that hangs over the entire FY 21 appropriations process for non-defense discretionary (NDD) programs. Last year, Congress broke a long-running stalemate by agreeing to budget caps for FY 20 and FY 21. They decided to front-load the increases, making spending decisions (relatively) easier […]




ndi

Indian manufacturers still deny drug quality problems and use same old rebuttals

Posted by Roger Bate The Economic Times of India covered our new paper today (see here). The paper published by the National bureau of Economic Research and not AEI as claimed by the Economic Times (see here), shows that Indian firms send their worst quality medicines to Africa. It is a shame that Indian Industry hack DG Shah continues to trot out the same arguments attacking us rather than addressing the paper’s findings. For example, he asks why did it take so long to publish a study [...]




ndi

Indian industry doth protest too much

Posted by Roger Bate (on behalf of the authors of the paper) India’s pharmaceutical industry wants its government to sue us because of our “smear campaign” against it (Click here) and if today’s media in India are correct, India’s government is considering it (Click here). This so-called campaign is actually an academic study which identifies uncomfortable data that some Indian companies, or their distributors, seem to be sending inferior medicines to Africa (s [...]




ndi

Is India right on its processes but wrong on its drug quality?

Posted by Roger Bate India’s government is contemplating suing my coauthors and I for defamation for some research we published last month. In our National Bureau of Economic Research working paper on the quality of Indian medicines exported to Africa we concluded that poorer quality products were intentionally being sent to Africa because of the continents generally weak oversight of drug quality. Litigation is rarely an effective method of finding the truth, more often a process to li [...]




ndi

Transcending boundaries: the role of pharmacists in gender identity services

There has been a surge in demand for gender identity services in the UK over the past five years. Although the current role of pharmacists is limited, their potential contribution within a multidisciplinary team supporting transgender patients is beginning to emerge.

To read the whole article click on the headline




ndi

Emergency Relief Package Yields Increased FDA Funding, OTC Revisions

March 30, 2020 – In addition to providing millions of Americans and many industries with financial support during the coronavirus outbreak, the emergency relief bill passed by Congress and signed into law by President Donald Trump on Friday accrues additional funding for the Food and Drug Administration’s coronavirus efforts and makes important changes to how […]




ndi

Oberland Capital nabs $1.05B raise for late-stage plays, handing out cash for royalties

Come on in, the water’s warm. After billions already raised by VC firms since the advent of the pandemic for life science companies, Oberland Capital has tossed more than $1 billion into the pot.




ndi

UNPA’s Israelsen: ‘We’ve had a good six weeks, but consumers have used some of their last spending power to buy supplements’

While dietary supplement sales have surged in recent months, the extent of the economic damage caused by the novel coronavirus and COVID-19 could lead to some very tough quarters as families and businesses start to run out of money.




ndi

Extending the Patentable Life of 3D Printers: A Lesson From the Pharmaceutical Industry

Modern innovation typically occurs one step-improvement at a time. Some clients initially question whether their new application of an existing technology is patentable. Usually, the answer is ‘yes.’ Under U.S. law (and most other jurisdictions), an innovation to an existing technology is patentable so long as at least one claim limitation is novel and non-obvious....… Continue Reading




ndi

'A wild ride': Expanding coronavirus testing takes center stage with reopening

Until millions of Americans can be tested weekly for coronavirus, states will walk blindly into restarts. But NIH director has a plan to ramp up.




ndi

Pharmacy Compounders Practicing Pursuant to Section 503A Can Get in the Mix: Compounding Shortage Drugs for Hospital Patients, with Some Limitations

By Karla L. Palmer



  • COVID19
  • Prescription Drugs and Biologics

ndi

Kao shares rise on coronavirus antibody findings




ndi

India and Pakistan's 'red zones' keep COVID-19 trajectory on rise




ndi

India faces dual crises as LG Polymers gas leak kills at least 11




ndi

Indians must stop spreading anti-Muslim fake news on WhatsApp




ndi

India's unemployment at record high amid tough COVID-19 lockdown




ndi

Nomination of Candidates for Director and Audit & Supervisory Board Member (PDF: 163KB/3P)




ndi

Nomination of Candidates for Director and Audit & Supervisory Board Member (PDF: 163KB/3P)




ndi

2-Hydroxyoleate, a nontoxic membrane binding anticancer drug, induces glioma cell differentiation and autophagy




ndi

With Coronavirus, ‘Nature is sending us a message’, says UN Environment Chief

Prof Andrew Cunningham from the Zoological Society of London said, “The emergence of COVID-19 was not only predictable, but it was also predicted (in the sense that) there would be another viral emergence from wildlife that would be a public health threat.”

 

























ndi

Tencent leads $9.4m funding in Indian self-publishing platform Pratilipi

The funding also saw the participation of Omidyar Network, Shunwei Capital, BCCL, and Nexus Venture Partners.

The post Tencent leads $9.4m funding in Indian self-publishing platform Pratilipi appeared first on DealStreetAsia.